MedPath

Relation Between Substance Use and Pain, in Patients Suffering or Surviving From Cancer and Followed in France

Completed
Conditions
Cancer
Pain
Substance Use
Interventions
Behavioral: Questionnaire (patient reported outcome)
Registration Number
NCT05684939
Lead Sponsor
University Hospital, Clermont-Ferrand
Brief Summary

Pain is one of the most prevalent symptoms during and after cancer. Pain can be the consequence of several situations (disease progression, surgery, and anticancer drugs). However, pain can frequently be associated with a substance use disorder (alcohol, tobacco, drugs, and illicit products such as cannabis). The relationship between substance use and pain is known to be complex and interdependent, i.e. pain can reinforce substance use and substance use can promote pain. However, few data in the literature are available on the use of psychoactive substances in relation to pain in the context of cancer (cancer patients and cancer survivors). Moreover, the scientific literature agrees on the fact that these elements are little studied and underestimated in the clinic.

The investigators hypothesize that, in cancer patients or cancer survivors, the prevalence of the use of psychoactive substances would be higher in the presence of pain, and would be associated with its intensity and its impact on the quality Health-Related Living (HRQoL).

The main objective of this study will be to compare, in an adult population of patients suffering from cancer or having had cancer, the prevalence of the consumption of psychoactive substances in painful patients compared to non-painful patients.

Detailed Description

Patients will answer to an online questionnaire thanks to associations of cancer patients and social networks, in order to explore their substance use and pain status.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2010
Inclusion Criteria
  • Adult patient, male or female, declaring himself as suffering or having suffered from cancer and recruited as such via appropriate communication systems (patient associations, etc.)
Exclusion Criteria
  • Difficulty to understand French language
  • Residence outside France (will be verified by the information from the department at the start of the questionnaire)
  • Patient close relative
  • Protected adults

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
cancer patients and cancer survivorsQuestionnaire (patient reported outcome)answer to an online questionnaire
Primary Outcome Measures
NameTimeMethod
substance useday 1

Legal: alcohol, tobacco, electronic cigarette, psychotropic drugs (benzodiazepines, z-drugs, and opioids), CBD, and other susbtances Illegal: cannabis, and other drugs

At least once in the past year, at least once in the past month, at least once in the past week, or at least once a day

Secondary Outcome Measures
NameTimeMethod
Neuropathic painday 1

DN4 interview questionnaire

Chemotherapy-induced peripheral neuropathyday 1

QLQ-CIPN20 questionnaire

Sociodemographic characteristics of patientday 1

age, sex, height, weight, body mass index, area of residence (urban or rural), socio-professional status (INSEE), and department

Pain severityday 1

Brief pain inventory

Intercurrent pathologiesday 1

open question

Oncological characteristicday 1

type of cancer, date of cancer diagnosis, and type of treatment (received and/or ongoing)

Anxiety and depressionday 1

HADS questionnaire

Analgesic useday 1

Ongoing analgesic drugs

Material and social deprivationday 1

EPICES questionnaire

Health-related quality of life and symptomsday 1

QLQ-C30 questionnaire

Trial Locations

Locations (1)

CHU Clermont-Ferrand

🇫🇷

Clermont-Ferrand, France

© Copyright 2025. All Rights Reserved by MedPath